{"name":"Leadiant Biosciences, Inc.","slug":"leadiant-biosciences-inc","ticker":"","exchange":"","domain":"","description":"Leadiant Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company has a pipeline of four drugs, with two in Phase 3 trials and two in Phase 1 trials, targeting various therapeutic areas including oncology and immunology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"STP206","genericName":"STP206","slug":"stp206","indication":"Other","status":"phase_1"},{"name":"Adagen","genericName":"Adagen","slug":"adagen","indication":"Adenosine deaminase deficiency","status":"phase_3"},{"name":"EZN-2279","genericName":"EZN-2279","slug":"ezn-2279","indication":"Hypertriglyceridemia","status":"phase_3"}]}],"pipeline":[{"name":"STP206","genericName":"STP206","slug":"stp206","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adagen","genericName":"Adagen","slug":"adagen","phase":"phase_3","mechanism":"Biologic","indications":["Adenosine deaminase deficiency"],"catalyst":""},{"name":"EZN-2279","genericName":"EZN-2279","slug":"ezn-2279","phase":"phase_3","mechanism":"EZN-2279 is an antisense oligonucleotide that inhibits apolipoprotein C-III (apoC-III) expression to reduce triglycerides and improve lipid metabolism.","indications":["Hypertriglyceridemia","Familial chylomicronemia syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxQMWE1d0ZBY1AzTW9DdVF0YjE5OGl4Q2Zfd0lDY0dHTGdaRjk3X0tCZzBtSGV1NXpHNkRFcER6dnBDZWpuenNzS1VXc2JhTmZDWW9WaVFZNmJ6eVBoN2dpVFFTZFhtdXFHLTllUlRHdUxYNGxreUpLN2s3Z1ljUTBWZVpOVTEwRVBWRXctNUN4a2l6SmNFME5EUnZSRnFjMjRjNlpZMHBTVjhEY3hPNzJPNjFWMDlTTzV4LXh4VlJ6aFlHNElXcXlYcElVQ0U0dEc3VG83UzFpRmtSWk5BZEJKa0NaU1RrczV1NF9LS2c2RnpQSmo0cVRIeUdLS1ZwSTNldU8tYWVneWpFM1hITUdCNkFPR0ZrVXE0SXVfOWdwLWhxb1A2dGNEa2FSXzFPMHU1WUs5TA?oc=5","date":"2026-03-04","type":"pipeline","source":"PR Newswire","summary":"Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight - PR Newswire","headline":"Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQVXNVNzNoTWlESHVXTHlPa1RnUVJNaUI2YXNMMW5BMFpPNThlamR1bl9VcDFseTJFOVg3VUQ2d25ZMVlCTXZKTEVFaGl5eUxtdUZ5Y1lmNWFxTzh4S3AyUmVjaGEtdzFJWXY2RnBpRUp1dHdVNjV1Qnd3S2pYVmhER1VDZzg2OWdmT3gtQ0U2VE9MQdIBVkFVX3lxTFBZWVAxZHVZdVJUdkVVdVdma0U3al9YVXpXRlVEOXhzWGhhQTI5UDRBX3BpMTRMU0VnNXRPLURucHNSbUo0eXMzejQ4S0lMYTUzb2R5U1ZB?oc=5","date":"2025-04-30","type":"deal","source":"Law360","summary":"VSL Probiotic Buyers Win Class Cert. In RICO Case - Law360","headline":"VSL Probiotic Buyers Win Class Cert. In RICO Case - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQZUVJU2U3Z1pVXzBVRnN4UzZ0QWZjeEhBLUJLbDMwR3JXalBETEpMc0ZTWVBGQjRENVFtOU1OYTlvVXQyeTc5RnFxM2RPa3VtMTBRQUVJdGlEbTRvUEp4VGtXVDVTUW40REVKMEV3THZPWUEyTkNPYW1XVUlTN3RmZE9EcjN1RWh6M3ZwMnZDRGdnS3k4dE5GT0tnVDZ2VEVJTTdHOTBGOA?oc=5","date":"2025-03-13","type":"pipeline","source":"Taylor Wessing","summary":"Unpacking the Dutch Leadiant cases: a legal battle with significant implications for the pharmaceutical industry - Taylor Wessing","headline":"Unpacking the Dutch Leadiant cases: a legal battle with significant implications for the pharmaceutical industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9mdnNWRkdHbk1qaWN0WjdUdER4MGJZRDBNSEYySUUyWjNDLTh1VnFMSHhoc3l1MkhLWVpTVkdOVnVjcUttSmZzVHZabzRHUnVCZnZqTWFyM2M4WTJiY3htMlI0NDNTM3U4dUVXSTJPVEZha29Z?oc=5","date":"2025-01-28","type":"pipeline","source":"WSJ","summary":"Exclusive | Drugmakers Show Restraint on Price Increases in New Trump Era - WSJ","headline":"Exclusive | Drugmakers Show Restraint on Price Increases in New Trump Era","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFAxYUlxMkREX1pQVFpQaGdYdTZmbG52UTM1TDhMR195ZGtWWkJDVHlYaWhlUjZrTHktTVlhVXJSTjQxOHVVcTQzWW5pVkhDT0R4Y1d5SzBxZW5aVHEwVGQxMml3aw?oc=5","date":"2020-05-10","type":"regulatory","source":"Basic Funerals and Cremation Choices","summary":"Nancy Elizabeth (Lewis) Parsons Obituary May 10, 2020 - Basic Funerals and Cremation Choices","headline":"Nancy Elizabeth (Lewis) Parsons Obituary May 10, 2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOZ1dsNWo2ZkxVWXZNdWtUTS0yNzFwRnRHMVExMk9FdWF3ZnhiSTdMWmRYRF9yM0JIVi1admZVa0YtbEs5cldFYlRNbFl6Q205V2tNcDRpZnUwZ2NzOXNSbTNtbVk5VlJ4alI2ZGVnUUl4UFBBQWlnbzZWdEJQYXFqb1NjMVY2VnA1RFlEcWVhWG9NeVdwY1dQa3ZuOA?oc=5","date":"2019-04-04","type":"regulatory","source":"BioSpectrum Asia","summary":"Japan approves first drug for ADA deficiency - BioSpectrum Asia","headline":"Japan approves first drug for ADA deficiency","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNd2FqZU5ZS2dBZnVxU3RpVFRob1UyT2pzNGNfRG1JYkFfaWVtVVdxUFlVNnpPeTJldFFsa2hRRjVublBLTjdncEdPOXFZNUUteHJtSWRMdzlZR25yMVhSdlgwbnhCZE9TSTFWeXU2cExPbnZUbkNsSnM5d1pTeHdVU3kyQy1nTWVkZHh0T2tKYU9IVTFLT05ib1lB?oc=5","date":"2019-01-30","type":"pipeline","source":"Gastroenterology & Endoscopy News","summary":"Probiotic Maker Loses False Claims Case - Gastroenterology & Endoscopy News","headline":"Probiotic Maker Loses False Claims Case - Gastroenterology & Endoscopy News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWEpBQS1yWGNyMGNZVWJnSHh4MTNMaWE2UlhZd0plLWxQRl9aLWVlc3J0bXM3aXVRa25kM3lNd3VqZm9IUkNBbFN3dVBzazJZbGQweEl3aUFOVnR0MGRROGNZSW5SMEtneVM2Tkp3dmdJYl9Ua2hJU1QzR2NHSDF5X0ZhLUMwMGlmaUJBZHZINmF1MTZWTE8wa0NNUDQ0T2ptNXExZkNsNUVrNW8?oc=5","date":"2017-03-10","type":"pipeline","source":"The Business Journals","summary":"Why a Gaithersburg drug company just gave itself a new name - The Business Journals","headline":"Why a Gaithersburg drug company just gave itself a new name","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_3":2},"enrichmentLevel":2,"visitCount":10,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}